RPTX insider transaction filings
Repare Therapeutics Inc. — 35 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-01-30. Screen RPTX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for RPTX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Repare Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-01-30 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P — 10% owner BVF I GP LLC — 10% owner BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Code (U): 5,309,432 · Code (U): 4,308,573 · Code (U): 548,938 | EDGAR |
| 2026-01-28 | 4 | Alves Sandra Isabelle Barros — SVP, Finance and CAO | Disposition to issuer (D): 31,622 · Disposition to issuer (D): 26,000 (derivative) @ $0 · Disposition to issuer (D): 24,500 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Forte Steve — EVP, CHIEF FINANCIAL OFFICER | Disposition to issuer (D): 56,786 · Disposition to issuer (D): 200,000 (derivative) @ $0 · Disposition to issuer (D): 85,000 (derivative) @ $0 · Disposition to issuer (D): 500,000 (derivative) @ $0 · Disposition to issuer (D): 325,800 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Civik Thomas — Director | Disposition to issuer (D): 7,500 | EDGAR |
| 2026-01-28 | 4 | SCHAFER CAROL — Director | Disposition to issuer (D): 8,000 · Disposition to issuer (D): 37,941 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | RHOADS ANN D — Director | Disposition to issuer (D): 4,000 | EDGAR |
| 2025-04-29 | 4 | Alves Sandra Isabelle Barros — SVP, Finance and CAO | Grant/award (A): 4,100 @ $0 · Grant/award (A): 24,500 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Forte Steve — EVP, CHIEF FINANCIAL OFFICER | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Koehler Maria — EVP, CHIEF MEDICAL OFFICER | Sale (S): 3,596 @ $1.14 | EDGAR |
| 2025-03-14 | 4 | Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 5,611 @ $1.14 | EDGAR |
| 2025-03-14 | 4 | Forte Steve — EVP, CHIEF FINANCIAL OFFICER | Sale (S): 6,884 @ $1.14 | EDGAR |
| 2025-03-14 | 4 | Segal Lloyd Mitchell — PRESIDENT AND CEO, Director | Sale (S): 21,179 @ $1.14 | EDGAR |
| 2025-03-06 | 4 | Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICER | Grant/award (A): 14,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Forte Steve — EVP, CHIEF FINANCIAL OFFICER | Grant/award (A): 14,000 @ $0 · Grant/award (A): 200,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Segal Lloyd Mitchell — PRESIDENT AND CEO, Director | Grant/award (A): 40,000 @ $0 · Grant/award (A): 237,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Civik Thomas — Director | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Kulkarni Samarth — Director | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Stein Steven H — Director | Grant/award (A): 54,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Morrison Briggs — Director | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Bonita David P — Director | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Molineaux Susan — Director | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | SCHAFER CAROL — Director | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | RHOADS ANN D — Director | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-04-01 | 4 | Forte Steve — EVP, CHIEF FINANCIAL OFFICER | Sale (S): 825 @ $4.62 · Sale (S): 789 @ $4.61 | EDGAR |
| 2024-04-01 | 4 | Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 450 @ $4.64 · Sale (S): 410 @ $4.66 | EDGAR |
| 2024-04-01 | 4 | Koehler Maria — EVP, CHIEF MEDICAL OFFICER | Sale (S): 500 @ $4.64 · Sale (S): 300 @ $4.66 | EDGAR |
| 2024-04-01 | 4 | Segal Lloyd Mitchell — PRESIDENT AND CEO, Director | Sale (S): 2,650 @ $4.62 · Sale (S): 2,491 @ $4.63 | EDGAR |
| 2024-03-27 | 4 | Forte Steve — EVP, CHIEF FINANCIAL OFFICER | Sale (S): 825 @ $4.79 · Sale (S): 825 @ $4.60 · Sale (S): 825 @ $4.62 | EDGAR |
| 2024-03-27 | 4 | Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 450 @ $4.78 · Sale (S): 450 @ $4.61 · Sale (S): 450 @ $4.62 | EDGAR |
| 2024-03-27 | 4 | Koehler Maria — EVP, CHIEF MEDICAL OFFICER | Sale (S): 500 @ $4.78 · Sale (S): 500 @ $4.60 · Sale (S): 500 @ $4.62 | EDGAR |
| 2024-03-27 | 4 | Segal Lloyd Mitchell — PRESIDENT AND CEO, Director | Sale (S): 2,650 @ $4.79 · Sale (S): 2,650 @ $4.64 · Sale (S): 2,650 @ $4.63 | EDGAR |
| 2024-03-05 | 4 | Forte Steve — EVP, CHIEF FINANCIAL OFFICER | Grant/award (A): 14,000 @ $0 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICER | Grant/award (A): 14,000 @ $0 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Koehler Maria — EVP, CHIEF MEDICAL OFFICER | Grant/award (A): 14,000 @ $0 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Segal Lloyd Mitchell — PRESIDENT AND CEO, Director | Grant/award (A): 40,000 @ $0 · Grant/award (A): 237,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Repare Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-01-28 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-22 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2025-08-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RPTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →